Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Stephanie Chawla

Physician Assistant, Medical Greenwich, CT Physician Assistant

NPI 1497809743 CMS profile 10840111

81 Holly Hill Ln, Greenwich, CT 06830

Open in the dashboard

General payments

$12,981

592 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Chawla of Greenwich, CT is reported in the CMS Open Payments database as having received $12,981 across 592 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,259 147
2024 General $3,633 162
2023 General $4,090 186
2022 General $1,998 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Chawla
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Stephanie Chawla were reported at $3,259. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Stephanie Chawla Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $1,998 $185 $55–$649 $149
2023 $4,090 $199 $58–$717 $160
2024 $3,633 $206 $62–$740 $164
2025 $3,259 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $4,399 186 payments
  2. AstraZeneca Pharmaceuticals LP $1,155 52 payments
  3. Exact Sciences Corporation $703 31 payments
  4. Merck Sharp & Dohme Corporation $573 24 payments
  5. Novo Nordisk Inc $561 27 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $521 32 payments
  7. ITI, Inc. $513 21 payments
  8. Idorsia Pharmaceuticals US Inc $309 17 payments
  9. Lilly USA, LLC $282 14 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $280 11 payments
  11. Other $3,685 177 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $12,981 592 payments
Products named General payments · program years 2022–2025
  1. QULIPTA $2,140 75 payments
  2. UBRELVY $1,639 57 payments
  3. VRAYLAR $847 50 payments
  4. VERQUVO $755 31 payments
  5. BREZTRI $710 30 payments
  6. Cologuard Collection Kit $703 31 payments
  7. XIFAXAN $534 33 payments
  8. FARXIGA $418 15 payments
  9. GEMTESA $345 20 payments
  10. CAPLYTA $315 13 payments
  11. Other $7,259 353 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

856

Median for Physician Assistant: 241

Drug cost

$58,360

Median for Physician Assistant: $4,110

Branded share of claims

22.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 16 $16,935
Mounjaro Tirzepatide Brand 13 $16,267
Farxiga Dapagliflozin Propanediol Brand 14 $8,898
Eliquis Apixaban Brand 12 $7,643
Omeprazole Generic 44 $713
Rosuvastatin Calcium Generic 48 $526
Methylprednisolone Generic 48 $473
Fenofibrate Fenofibrate Nanocrystallized Brand 20 $454
Atorvastatin Calcium Generic 45 $434
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 15 $423

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$548 — —
QULIPTA
$444 — —
BREZTRI
$291 — —
VRAYLAR
$229 — —
XIFAXAN
$192 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

592 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record